At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
pembrolizumab; vorinostatdrug
Likely dose
pembrolizumab; vorinostat 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Basket Trial Evaluating the Efficacy of a Combination of Pembrolizumab and Vorinostat in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating pembrolizumab; vorinostat for Squamous Cell Lung Cancer and 5 related conditions. Completed, enrolled 112 participants across 14 sites.
Detailed Summary
Interventional study evaluating the efficacy of an immunotherapy (pembrolizumab) in combination with a targeted therapy (vorinostat) in patient with recurrent and/or metastatic squamous cell carcinoma (localisations : head and neck, lung, cervix, anus, vulva, and penis)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Lung Cancer, Vulvar Cancer, Penile Cancer, Cervix Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer
CountriesFrance
CollaboratorsMerck Sharp & Dohme LLC, Fondation ARC, ERA-NET
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartOct 2020
Primary CompletionDec 2022
Study CompletionNov 2024
TodayJul 2026
First PostedApr 22, 2020
Enrollment StartOct 28, 2020
Primary CompletionDec 15, 2022
Study CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.2 years ago
Interventions
pembrolizumab; vorinostatdrug
Pembrolizumab: 200 mg every 3 weeks, up to 35 administrations Vorinostat: 400 mg once daily, until progression